- Home
- ACET vs EEA Comparison
ACET vs EEA Comparison
Compare ACET & EEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- EEA
- Stock Information
- Founded
- ACET 1947
- EEA 1986
- Country
- ACET United States
- EEA Germany
- Employees
- ACET N/A
- EEA N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- EEA Trusts Except Educational Religious and Charitable
- Sector
- ACET Health Care
- EEA Finance
- Exchange
- ACET Nasdaq
- EEA Nasdaq
- Market Cap
- ACET 70.3M
- EEA 57.7M
- IPO Year
- ACET N/A
- EEA N/A
- Fundamental
- Price
- ACET $0.72
- EEA $9.13
- Analyst Decision
- ACET Buy
- EEA
- Analyst Count
- ACET 6
- EEA 0
- Target Price
- ACET $6.00
- EEA N/A
- AVG Volume (30 Days)
- ACET 324.2K
- EEA 9.2K
- Earning Date
- ACET 03-06-2025
- EEA 01-01-0001
- Dividend Yield
- ACET N/A
- EEA 1.92%
- EPS Growth
- ACET N/A
- EEA N/A
- EPS
- ACET N/A
- EEA N/A
- Revenue
- ACET N/A
- EEA N/A
- Revenue This Year
- ACET N/A
- EEA N/A
- Revenue Next Year
- ACET N/A
- EEA N/A
- P/E Ratio
- ACET N/A
- EEA N/A
- Revenue Growth
- ACET N/A
- EEA N/A
- 52 Week Low
- ACET $0.69
- EEA $7.45
- 52 Week High
- ACET $2.40
- EEA $9.26
- Technical
- Relative Strength Index (RSI)
- ACET 37.26
- EEA 50.85
- Support Level
- ACET $0.74
- EEA $9.06
- Resistance Level
- ACET $0.91
- EEA $9.28
- Average True Range (ATR)
- ACET 0.06
- EEA 0.10
- MACD
- ACET -0.00
- EEA -0.03
- Stochastic Oscillator
- ACET 12.61
- EEA 22.62
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.